The merger between Tilray Inc TLRY and Aphria was a “perfect match” and the entity could generate pro-forma sales growth of 33% between fiscal 2021 and 2024, according to Jefferies.
The Tilray Analyst: Owen Bennett upgraded the rating for Tilray from Underperform to Buy, while raising the price target from $4.77 to $23.
The Tilray Thesis: The company has a stronger sales and profit growth profile than its closest Canadian peers, Canopy Growth Corp CGC and Cronos Group CRON, Bennett said in the upgrade note.
Tilray also has a “more attractive positioning to capture an EU upside, and equally compelling optionality for US THC,” he added.
“In Europe, the market is now picking up, while Tilray's scale and Aphria's unique German positioning make it perfectly suited to succeed. And in the US, the combined company's broader consumer goods portfolio and strong BS supports excellent optionality around both US THC and CBD,” the analyst wrote.
“Aphria's strong portfolio of 1.0 (flower) brands across targeted segments and price points sees the combined company with the number one value share in Canada at 17.1%,” he further stated.
TLRY Price Action: Shares of Tilray had risen by 16.77% to $20.05 at the time of publication Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.